Zydus and Apollo bring Guardant's multi-cancer blood test to India
The Shield test, already exclusive to Zydus, will now screen across Apollo's network. No financial terms disclosed.
— 2 earlier stories on Zydus Lifesciences Ltd. →What's new
- Zydus signed an MoU with Apollo Hospitals to offer the Shield multi-cancer detection test across Apollo's network.
- The blood test screens for ten cancers and has FDA Breakthrough Device Designation.
- Targets asymptomatic adults aged 45 and older at average risk.
Why this matters
This MoU should give Shield wider reach through Apollo's hospitals and diagnostic centres. Early detection is aligned with India's rising cancer burden. But Zydus provided no revenue forecasts or investment commitments, limiting near-term financial impact.
What we're watching
- Number of tests administered and any revenue-sharing model that emerges.
- Reimbursement or insurance coverage for the test in India.
- Competing liquid biopsy launches from other players.
The full read
Zydus Lifesciences is deepening its diagnostics push by roping in Apollo Hospitals for the Shield Multi-Cancer Detection test. The blood test, developed by Guardant Health and already under exclusive rights with Zydus, screens for ten common cancers and holds FDA Breakthrough Device status. Apollo's network of hospitals, clinics, and diagnostic centres could meaningfully expand reach. But this remains a non-binding MoU with zero financial detail. No revenue split, no investment outlay, no volume target. For a company with a market cap exceeding ₹1,10,000 crore, that limits the near-term materiality. Zydus has bigger catalysts to watch: a Warning Letter at Baddi and a November PDUFA for a US liver drug. The partnership is strategically sound, but investors have no numbers to model.
Questions answered
- What is the Shield Multi-Cancer Detection test?
- It's a blood-based test that screens for ten common cancers. Developed by Guardant Health, it has FDA Breakthrough Device Designation. Zydus has exclusive rights to offer it in India.
- What does the MoU with Apollo add?
- It allows the test to be offered across Apollo's network of hospitals, clinics, and diagnostic centres, which could expand patient access beyond Zydus's own channels.
- Did Zydus disclose any financial projections?
- No. The filing provided no investment, revenue, or volume numbers, making it a strategic MoU without near-term earnings visibility.
- How significant is this for a company of Zydus's size?
- With a market cap over ₹1,10,000 cr, the MoU is too small in disclosed detail to move the needle. But it strengthens the diagnostics narrative alongside other pipeline events.
- What other key events are on Zydus's radar?
- A US FDA warning letter for the Baddi plant (June 2026) and an US liver drug with a PDUFA date in November 2026.
Zydus Lifesciences Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ZYDUSLIFE →- 3 Jul 2026 · 12:18 PM IST Zydus and Apollo bring Guardant's multi-cancer blood test to India
- 33d ago USFDA flags purified talc at Zydus's Baddi plant in Warning Letter
- 40d ago Zydus's US liver drug gets a faster FDA look. A decision comes Nov 2026.